Summary The prognostic factors for response to chemotherapy and the prognostic impact of response status on survival, relative to other prognostic variables, were evaluated among 53 responding (9 complete responses; 44 partial responses) and 165 non-responding patients with inoperable adenocarcinoma of the lung (ACL). Multiple logistic regression analysis, including 27 pretreatment variables, revealed that the only significant predictor of response was bidimensionally measurable disease parameter (P=0.02), followed by brain metastases that were negatively correlated to response, although insignificantly (P=0.10). Univariate landmark analyses among patients alive at 8, 12, 16 and 24 weeks showed a trend towards better survival for responders compared with non-responders, but did not reach a significant level at any time (P values 0.78, 0.57, 0.23 and 0.12, respectively). Death hazard ratios for responders to non-responders were 0.91, 0.89, 0.79 and 0.73. Muftivariate regression analysis among patients alive at 16 weeks demonstrated a significant impact on survival for performance status, non-radical tumour resection, liver metastases and LDH, while the impact of response status in comparison was weak and insignificant. This reflects the unsatisfactory treatment results achieved in inoperable ACL, with the majority of responses being partial, and calls for improvement of the cytostatic treatment currently available.
Chemotherapy has been widely employed in the treatment of non-resectable adenocarcinoma of the lung (ACL), but without substantial success. Only 20-40% of the patients achieve an objective response with the best treatment regimens and the majority of responses observed are only partial (S0rensen et al., 1988a; S0rensen & Hansen, 1988) . A prolonged survival for patients on chemotherapy compared with untreated patients has recently been documented in a multicentre trial, showing that the administration of chemotherapy can improve, in a modest way, the overall survival of treated patients with advanced non-small cell lung cancer (P=0.02) (Rapp et al., 1988) . The impact of response status on survival, relative to other potential prognostic factors, is of interest for a detailed characterisation of the prognosis in patients treated with chemotherapy.
The comparison of survival distributions between responding and non-responding patients presents difficulties (Anderson et al., 1983) . Comparing pretreatment variables for frequencies of patients eventually achieving a response during chemotherapy is hampered by different durations of the periods 'at risk' for response for individual patients. Patients with a long survival may be on study and have the opportunity to respond for a longer time than patients who die early. Thus, analyses which do not take this into account may in part reflect prognostic factors for survival rather than prognostic factors for response.
Another point is that a statistical procedure testing the equality of survival distributions between the responder and non-responder groups only demonstrates an association between response and survival, not between cause and effect (Weiss et al., 1983) . This association may not be of any relevance to the efficacy of treatment, but response may simply serve as an indicator for patients with otherwise positive prognostic features.
The response status at a given landmark time may thus be considered a possible prognostic factor for the future survival of patients, giving additional information about the individual patient. Accordingly, the response status has been discussed as a potential prognostic variable, e.g. in studies by the Eastern Cooperative Oncology Group (Ruckdeschel et al., 1985 (Ruckdeschel et al., , 1986 (Eagan et al., 1986) and survival (Rapp et al., 1988 , Eagan et al., 1986 (WHO, 1981) by the pathologist at the respective hospitals. Only patients satisfying the criteria for ACL were included.
Subtyping of ACL was done retrospectively and blinded for the clinical results by one pathologist. The subtyping was based on histological material from 220 patients while cytological material alone was available from 39 patients (S0rensen et al., 1988b WHO criteria (WHO, 1979) . In case of complete (CR) or partial remission (PR) the date of the first (Armitage, 1971 (WHO, 1979) . Accordingly, the survival for patients classified as having a response no later than at 4 weeks and who were alive at 8 weeks was compared with the survival of non-responding patients alive at 8 weeks using KaplanMeier plots (Kaplan & Meier, 1958) and the log rank test (Peto et al., 1977 An analysis was performed, in which these variables were tested for prediction of response among the patients surviving 16 weeks using multiple logistic regression (Cox, 1970) . Similarly, the pretreatment variables were included together with response status in an analysis of future survival among patients alive at 16 weeks using Cox's proportional hazards model (Cox, 1972) . This particular group of patients was chosen for analysis in advance because a substantial part of the responses had occurred at that time and the majority of patients were still alive (Table IV) .
The proportional-hazard assumption, which is a condition for applying the Cox multivariate analysis on these data, was checked by graphical and numerical methods (Anderson, 1982) and found not to be violated.
Results
A total of 259 patients were entered into the trial. Response assessment was possible in 218 patients who had either measurable (110 patients) or evaluable disease (108 patients), and the following analysis is based on these patients. The disease parameters are listed in Table V . Fifty-three patients achieved a complete (9 patients) or partial response (44 patients) (S0rensen et al., 1987) . No attempt was made to distinguish between the prognostic implications of these two response types, but for the purpose of analysis patients were categorised as either responders (CR or PR) or nonresponders. The responses to chemotherapy were in 50 patients documented by chest X-rays and in three patients exclusively by superficial lymph nodes (Table V) (Table VI) . No other pretreatment variables showed any significant influence.
Discussion
Together with response duration and overall survival, evaluation of response rates plays a key role in medical oncology, especially in phase II trials but also in phase III trials. The present state of chemotherapy for inoperable ACL indicates that at the most one-third of the patients included achieve a response to the regimens available today and complete responses seldom occur (S0rensen et al., 1988a; S0rensen & Hansen, 1988) . Assessment of the influence of various prognostic factors for response is therefore pertinent when evaluating response data, in the stratification of patients, and when selecting the inclusion criteria.
Univariate analysis of 27 variables for prediction of response in this study increases the possibility of statistical significance occurring by chance.. The finding of haemoglobin >7.5mm as a predictor of low response rate (Ruckdeschel et al., 1986) . Eagan et al. (1979) (Rapp et al., 1988) or Karnofsky performance status and the presence of bone metastases (O'Connell et al., 1986) to be of independent prognostic significance for the attainment of response.
One method of analysing the results of treatment for nonsmall cell lung cancer is to compare the survival for responders and non-responders (Aisner & Hansen, 1981) . Unfortunately, such an analysis is associated with major methodological and interpretational pitfalls. The frequently used method of analysing survival by response, which involves dividing patients into two groups according to whether or not they ever achieve a response, is invalid (Anderson et al., 1983 (Mantel & Byar, 1974) and the landmark method (Anderson et al., 1983) . The latter method is used in the present study.
A correlation between response and survival has previously been reported in clinical trials of patients with non-small cell lung cancer by both the Mantel-Byar method (Ruckdeschel et al., 1985 (Ruckdeschel et al., , 1986 and the landmark method (Ruckdeschel et al., 1985) . These two large studies included 432 and 486 NSCLC patients, respectively.
The present study evaluated the relationship between In the present study, patients with ACL responding to the drugs lived only slightly longer than non-responding patients, and response status was not a major predictor of future survival. An explanation of this observation may be that most of the responses, both in this study and in others (S0rensen et al., 1988a; S0rensen & Hansen, 1988) , were partial. Some caution must be exerted when intepretating these data. Firstly, a major disadvantage of the landmark method is that the results depend on the selection of an arbitrary landmark time, and conclusions of the analysis may therefore differ according to the landmark chosen (Anderson et al., 1983) . However, none of the four landmark analyses performed in this study showed any significant differences in survival between responding and nonresponding patients.
Secondly, observer variation in response assessment may account for some of the differences in response rates observed in different studies (Warr et al., 1984) and may also affect the significance of the correlation to survival. Efforts were taken to diminish errors in response assessment, by using two observers who strictly adhered to the WHO guidelines for response assessment (WHO, 1979) . This, however, does not completely eliminate the possibility of observer variations.
In conclusion, a response to the cytotoxic drugs used in the present study was not a significant predictor of future survival among patients with inoperable ACL. Patients having measurable lesions had a greater likelihood of responding than patients with evaluable lesions, and patients with brain metastases seldomly responded. This may be of importance for the patient selection in future studies and for the interpretation of the results.
